Wang Xiaodong, a director and Chair of the Scientific Advisory Board of BeOne Medicines Ltd. (NASDAQ:ONC), filed a Form 4 on September 10, 2026, disclosing the sale of American Depositary Shares and the exercise of a share option on September 8, 2026.

Key Highlights

  • Option exercise: Wang Xiaodong exercised a share option (transaction code M) to acquire 31,027 American Depositary Shares at an exercise price of $36.9 per share on September 8, 2026.
  • ADS sales: A total of 31,260 American Depositary Shares were sold across eight separate transactions on September 8, 2026, at weighted average prices ranging from $345.383 to $351.2542.
  • 10b5-1 plan: According to the filing, all sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2026.
  • Derivative position reduced: Wang Xiaodong exercised 403,351 ordinary shares' worth of a share option (exercise price $2.84 per ordinary share), leaving 1,210,079 share options beneficially owned directly following the transaction.
  • Direct ADS balance: Following all reported transactions, the reporting person holds 0 American Depositary Shares directly, down from positions held prior to the reported transactions.
  • Indirect ordinary share holdings: The filing reports indirect ordinary share holdings of 1,025,063 shares via a family trust, 3,953,100 shares via Wang Investment LLC, and 50 shares held by the reporting person's spouse.

Wang Xiaodong's September 2026 ADS Transactions at BeOne Medicines

According to the Form 4 filed with the SEC, Wang Xiaodong - listed as a director and Chair of the Scientific Advisory Board of BeOne Medicines Ltd. - conducted multiple securities transactions on September 8, 2026. The filing identifies the issuer as BeOne Medicines Ltd. with the ticker symbol ONC on NASDAQ. Each American Depositary Share represents 13 ordinary shares, as disclosed in the filing's footnotes.

The filing reports that Wang Xiaodong exercised a share option (transaction code M) covering 31,027 American Depositary Shares at a price of $36.9 per share, acquiring those shares directly. On the same date, he sold those shares and additional shares across eight tranches under transaction code S. The eight sale transactions involved 1,181, 2,841, 1,517, 1,721, 7,492, 10,688, 6,569, and 6,278 American Depositary Shares, respectively, at weighted average prices of $345.383, $346.1575, $347.3915, $348.0126, $348.3146, $349.2834, $350.2741, and $351.2542. The filing notes that each weighted average price reflects sales across a range of individual transaction prices and that full details are available upon request to the issuer or SEC staff.

In Table II, the filing discloses the exercise of 403,351 ordinary shares underlying a share option with a conversion price of $2.84 per ordinary share, with an expiration date of November 15, 2026. The filing notes this option vested 25% on July 13, 2017, with the remainder vesting in 36 successive equal monthly installments. Following the reported transactions, 1,210,079 share options remain beneficially owned directly. The filing also discloses direct ordinary share holdings of 4,588,113 shares, with additional indirect holdings disclaimed by the reporting person.

What Was Disclosed

The filing discloses the exercise of a share option and the sale of American Depositary Shares by BeOne Medicines director Wang Xiaodong on September 8, 2026, all conducted under a Rule 10b5-1 trading plan adopted June 9, 2026.